Recently the number of companies based at Pivot Park reached the milestone of 50! Newcomers PharmaCytics and Sterk Schakelen joined the Community and became part of our hotspot for pharmaceutical innovation. “It is amazing that in less than six years’ time, Pivot Park has attracted over 50 companies who chose to base here and become part of our community,” says Rob Prins, chairman of Pivot Park’s board. “Our pharmaceutical R&D infrastructure and successful community provides entrepreneurs with opportunities to accelerate their business and contribute to a healthier society. I am very glad that an increasing number of companies becomes aware of this and chooses to establish their companies here.

PharmaCytics offers a oral drug delivery solution, based on an advanced prodrug approach. The technology exploits intestinal transporter proteins meaning that active transport is promoted. “Our technology deals with multiple issues associated with drug absorption at the same time, as opposed to many currently existing techniques that often focus on solubility only. In our experience this means that products that were hampered or stopped in R&D can be revived”, tells Han van ‘t Klooster, CEO of PharmaCytics. “Pivot Park offers us a community where other pharmaceutical companies, also active in R&D, are present. Furthermore relevant CRO’s offer their services in e.g. the area of scaling up and regulatory affairs. We also see that some of these R&D companies could become our customers. Read further

Sterk Schakelen became also a member of the Pivot Park Community. “We focus on developing an effective web presence, as well as collateral communications for our clients in life sciences,” explains Sterk Schakelen’s CEO Nienke Oldenburg, formerly a biochemist at Organon (Teknika), now a marketer, project manager and a web communications specialist. “On our client’s behalf, we communicate in the language of their industry and in the language of their clients. I am looking forward to support the Pivot Park Community in this!” Read further